We also evaluated the predictive gain of using genetic information in the practical assessment tool, including APOE e4 status and a polygenic risk score for AD, to help determine whether a gain in prediction would offset the loss from decreased practicality of the tool. This evidence concerns the gene APOE and Alzheimer disease.